title: Efalizumab-induced lupus-like syndrome.
authors.forename: Hélene
authors.initials: H
authors.lastname: Durox
authors.forename: Agnès
authors.initials: A
authors.lastname: Sparsa
authors.forename: Véronique
authors.initials: V
authors.lastname: Loustaud-Ratti
authors.forename: Sorilla
authors.initials: S
authors.lastname: Prey
authors.forename: Guillaume
authors.initials: G
authors.lastname: Gondran
authors.forename: Petrus
authors.initials: P
authors.lastname: Manea
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Vidal
authors.forename: Christophe
authors.initials: C
authors.lastname: Bedane
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001219:Aspartate Aminotransferases / Q000097:blood; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced*; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D013577:Syndrome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; C472181:efalizumab